Extracorporeal Membrane Oxygenation System Market Analysis & Forecast: 2026-2033
The global extracorporeal membrane oxygenation system market is estimated to be valued at USD 395 Mn in 2026 and is projected to grow at a CAGR of 5.4% during the forecast period (2026-2033), reaching USD 571 Mn by 2033. This growth can be attributed to increasing incidence of cardiopulmonary disorders such as acute respiratory distress syndrome (ARDS), cardiac arrest, and heart failure and growing demand for advanced life-support systems like ECMO in critical care settings.
The global extracorporeal membrane oxygenation system market is projected to grow steadily during the forecast period. This is primarily due to rising incidence of severe respiratory and cardiac failure cases, increasing adoption of extracorporeal life support in intensive care units, and growing prevalence of conditions like acute respiratory distress syndrome (ARDS), sepsis, and cardiac arrest. Technological advancements in ECMO systems, improved portability and safety features, and expanding use in neonatal and pediatric care are also supporting market growth.
Extracorporeal membrane oxygenation (ECMO) is a life-support system that provides respiratory and/or cardiac support to patients with severe respiratory and/or circulatory failure. The ECMO circuit comprises cannulas, a pump, a gas blender, and a membrane oxygenator, which oxygenates the blood and removes carbon dioxide through extracorporeal gas exchange.
Potential indications for ECMO include severe acute respiratory distress syndrome (ARDS), acute hypercapnic respiratory failure, cardiogenic shock or cardiac arrest (ECPR), bridge to lung transplantation, and primary graft dysfunction following lung transplantation. It is also used in pulmonary hypertension with right ventricular failure.
Rising adoption of ECMO systems in critical care ICUs is expected to boost market growth during the assessment period. Similarly, technological advancements in ECMO components are increasing the adoption rate. Innovations such as advanced oxygenators, centrifugal pumps, heparin-coated cannulas, and improved circuit designs are enhancing safety and performance.
Leading companies are developing advanced extracorporeal membrane oxygenation technologies to meet the evolving needs of the healthcare industry. For instance, in April 2025, Eurosets launched two latest-generation extracorporeal cardiopulmonary support devices: Xtreme Rescue and Landing Breathe. The company also launched a new ECMO machine for emergency situations.
According to Coherent Market Insights’ latest extracorporeal membrane oxygenation system market analysis, venoarterial segment is set to account for the largest market share of 48% in 2026. This dominance can be attributed to its widespread use in managing severe cardiac and cardiopulmonary failure, especially in patients experiencing cardiogenic shock, cardiac arrest, and post-cardiotomy complications. Each year, over 350,000 Americans suffer out-of-hospital sudden cardiac arrest, with nearly 90% resulting in death, while about 290,000 cardiac arrests occur in hospitals.
VA ECMO provides both cardiac and respiratory support, making it the preferred modality for critically ill patients requiring immediate hemodynamic stabilization. Rising prevalence of cardiovascular diseases, increasing adoption of advanced life-support technologies in intensive care units, and rising demand for extracorporeal cardiopulmonary resuscitation (ECPR) are also expected to boost growth of this segment during the forecast period.
To learn more about this report, Request Free Sample
Based on application, respiratory segment is expected to account for the largest market revenue share of 44% in 2026. This is mostly due to increasing prevalence of severe respiratory disorders such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), severe pneumonia, and respiratory failure, which often require advanced life-support interventions. Chronic Obstructive Pulmonary Disease (COPD) affects about 11% of adults worldwide and is characterized by progressive airflow limitation resulting from airway or alveolar abnormalities.
ECMO serves as a critical treatment option for patients whose lungs are unable to provide adequate oxygenation despite conventional mechanical ventilation and other therapies. Growing incidence of respiratory infections, rising air pollution levels, increasing smoking-related lung diseases, and the long-term pulmonary complications associated with viral outbreaks are also fueling demand for respiratory ECMO systems.
Rising Prevalence of Cardiopulmonary Diseases: Increasing prevalence of cardiopulmonary diseases is providing a strong impetus for the growth of extracorporeal membrane oxygenation system market. There is a spike in the cases of acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), heart failure, and cardiac arrest. This, in turn, is driving demand for ECMO systems as advanced life-support solutions.
According to the World Health Organization (WHO), chronic respiratory diseases (CRDs) are the sixth leading cause of death in the WHO European Region, accounting for nearly 400,000 deaths annually, with almost 80% of these deaths attributed to COPD. This growing burden of severe respiratory disorders is increasing the need for advanced respiratory support technologies such as ECMO systems, particularly for patients who do not respond adequately to conventional ventilation therapies, thereby supporting market growth.
Similarly, expansion of extracorporeal cardiopulmonary resuscitation (ECPR) is supporting market expansion. Increasing use of extracorporeal membrane oxygenation (ECMO) during cardiac arrest and emergency resuscitation procedures is broadening the technology's clinical applications and driving demand for ECMO systems.
Rise of Portable and Compact ECMO Systems: Increasing popularity of portable extracorporeal member oxygenation systems is a key growth-shaping market trend. Leading manufacturers are introducing lightweight, transportable ECMO devices that facilitate patient transfers and emergency care outside traditional hospital settings. One such example is Hemovent’s launch of the MOBYBOX® portable pneumatic ECMO/ECLS system in May 2024.
|
Current Event |
Description and its Impact |
|
Severe hyperoxia associated with higher mortality in VA-ECMO patients |
|
|
Expanding ECMO use in cardiogenic shock and ECPR despite high mortality rates |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
To learn more about this report, Request Free Sample
North America is expected to account for around 40% of the global extracorporeal membrane oxygenation (ECMO) system market share in 2026. This can be attributed to rising prevalence of cardiovascular and respiratory diseases, increasing adoption of advanced life-support technologies, and presence of well-established critical care infrastructure. Growing use of ECMO in intensive care units (ICUs) for managing severe heart and lung failure is also supporting market expansion.
Increasing burden of cardiovascular diseases is playing a key role in boosting North America ECMO market. According to the U.S. Centers for Disease Control and Prevention (CDC), heart disease remains the leading cause of death in the United States, accounting for 683,491 deaths. The growing number of patients requiring advanced cardiac and respiratory support is fueling adoption of ECMO systems across hospitals and specialty care centers.
Asia Pacific is set to emerge as a happy hunting ground for manufacturers of extracorporeal membrane oxygenation systems during the forecast period, registering a CAGR of 6.0%. This is mostly due to rising healthcare investments, increasing incidence of cardiovascular and respiratory disorders, expanding ICU capacity, and growing awareness about advanced life-support therapies.
Rising burden of cardiovascular diseases is providing a major stimulus for the growth of Asia Pacific extracorporeal membrane oxygenation system market. Cardiovascular diseases (CVDs) are the leading cause of death in India, responsible for approximately 25% of all deaths and 45% of NCD-related mortality. Similarly, increasing geriatric population and expansion of neonatal and pediatric ECMO applications are expected to boost sales of extracorporeal membrane oxygenation systems in the region during the projection period.
The United States is expected to remain the leading market for Extracorporeal Membrane Oxygenation (ECMO) systems during the forecast period. This is primarily due to its advanced healthcare infrastructure, high adoption of cutting-edge critical care technologies, and increasing prevalence of severe cardiovascular and respiratory disorders. Respiratory diseases impose a major health and economic burden in the United States, affecting over 35 million people with chronic conditions such as asthma and COPD and costing more than $170 billion annually. Rising utilization of ECMO in intensive care units (ICUs), growing availability of specialized ECMO centers, and ongoing investments in life-support technologies are also boosting market growth in the nation.
The extracorporeal membrane oxygenation system market in China is anticipated to witness steady growth throughout the assessment period. This is due to rapid healthcare infrastructure development, increasing incidence of cardiovascular and respiratory diseases, and rising investments in critical care services. According to the WHO, China has nearly 100 million people living with COPD, representing about 25% of the global disease burden. Similarly, increasing demand for ECMO in critical care settings, particularly during cardiac surgeries, lung transplantation procedures, and the management of severe respiratory failure, is also supporting market expansion in China.
Some of the major players in extracorporeal membrane oxygenation system market are Medtronic, Getinge AB, LivaNova PLC, Terumo Corporation, XENIOS AG, OriGen Biomedical, EUROSETS, NIPRO, and MicroPort Scientific Corporation.
Top extracorporeal membrane oxygenation system companies are adopting various organic and inorganic strategies to boost their revenue as well as gain a competitive edge in the industry. These include new product launches and approvals, mergers, partnerships, acquisitions, and distribution agreements.
Leading manufacturers are also investing heavily in research and development activities to enhance system performance, improve patient safety, and expand the clinical applications of ECMO technology. They are focusing on developing portable and user-friendly ECMO systems to support emergency care, transport, and intensive care settings.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 395 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.4% | 2033 Value Projection: | USD 571 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Medtronic, Getinge AB, LivaNova PLC, Terumo Corporation, XENIOS AG, OriGen Biomedical, EUROSETS, NIPRO, and MicroPort Scientific Corporation |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
